Cyclacel Pharmaceuticals (NASDAQ:CYCC) has announced that it received £2.3M (~$2.9M) as a R&D tax credit from HMRC, the tax agency of the United Kingdom government. The tax credit is based on R&D costs incurred in the year ended Dec. 31, 2023. The Co. expects to receive an additional ~$0.8M following confirmation of a change in the rate of tax credit regarding 2023 expenditures.

Cyclacel Pharmaceuticals（纳斯达克：CYCC）宣布从英国政府税务机构HMRC获得230万英镑（约290万美元）的研发税收抵免。税收抵免基于截至2023年12月31日的年度内产生的研发成本。在确认2023年支出的税收抵免率发生变化后，该公司预计将额外获得约80万美元。

'We appreciate this governmental support as we evaluate potential precision medicine approaches for both our clinical candidates, oral fadraciclib and oral plogosertib, to address oncology indications with large unmet medical needs,” said Paul McBarron, Executive VP, Finance & COO. More on Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals announces registered direct and private placement offering Seeking Alpha’s Quant Rating on Cyclacel Pharmaceuticals Historical earnings data for Cyclacel Pharmaceuticals Financial information for Cyclacel Pharmaceuticals .

财务与首席运营官执行副总裁保罗·麦克巴伦（PaulMcBarron）表示：“我们感谢政府的支持，因为我们评估了我们的临床候选人口服fadraciclib和口服plogosertib的潜在精准医学方法，以解决大量未满足医疗需求的肿瘤学适应症。”。更多关于Cyclacel Pharmaceuticals的信息Cyclacel Pharmaceuticals宣布注册直接和私募发行，寻求Alpha对Cyclacel Pharmaceuticals的定量评级Cyclacel Pharmaceuticals的历史收益数据Cyclacel Pharmaceuticals的财务信息。